Harrow Inc reports 36% revenue growth to $272.3 million in 2025, with EBITDA up 54% to $61.9 million, fueling bullish sentiment.
Harrow Inc’s stock traded at $33.10 on June 8, reflecting a bullish outlook driven by accelerating financial performance. The company reported 2025 revenue of $272.3 million, a 36% year-over-year increase, while EBITDA surged 54% to $61.9 million. Growth is attributed to expanding prescription volumes and operational leverage across its ophthalmic portfolio.
The company’s transformation into a leading branded eye care player positions it in multi-billion-dollar markets, including dry eye disease and the $8 billion anti-VEGF segment. Analysts highlight Harrow’s undervaluation relative to peers, citing a trailing P/E of 9.64 and forward P/E of 232.56. The global ophthalmic drugs market is projected to nearly double over the next decade, supported by aging demographics and rising disease prevalence.